Медицинский вестник Юга России (Sep 2023)
Evaluation of the effectiveness of the proposed therapy on energy metabolism parameters in patients with chronic liver lesions on the background of secondary immunodeficiency state
Abstract
Objective: to study the effect of a combination of azoximer bromide (AB) and human placenta hydrolysate (HPН) on metabolic processes in patients with chronic liver lesions on the background of secondary immunodeficiency. Materials and methods: 95 patients with chronic liver pathology on the background of secondary immunodeficiency (VIDS) aged 35 to 56 years were examined. The main group is 45 people, and the comparison group is 50 people. After a general clinical and bacteriological examination, all patients were subjected to the study of metabоlic processes. The assessment of metabolic disorders was carried out by the level of macroergic compounds in the hemolysate of the washed suspension of erythrocytes of patients by thin-layer chromatography. In addition to treatment with conventional methods, patients who were under observation were additionally prescribed a combination of drugs — bromine azoximer and human placenta hydrolysate. Patients of the comparison group received milk thistle preparations as a hepatoprotector and did not use any immunoactive drugs. Results: when studying the state of indicators of metabolic disorders after the completion of treatment, it was found that patients in the main group who received AB and HPН had almost complete normalization on the part of the studied indicators, which cannot be said about patients from the comparison group who received only conventional drugs in average therapeutic doses in the treatment complex. Conclusions: from the data obtained, it is possible to judge the positive effect of AB and HPН on the indicators of the state of energy homeostasis and consider it pathogenetically justified and clinically promising to include their combination in the complex of treatment of patients with CLP against the background of VIDS.
Keywords
